Anteris Reports 2024 Financial Results and Provides Corporate Update

The company’s revenue grew by 25% year-over-year, driven by the expansion of its cloud-based services and the adoption of its innovative technologies.

Revenue growth of 25% year-over-year

Successful U.S. IPO onto Nasdaq

Expansion of cloud-based services

Adoption of innovative technologies

The company’s cloud-based services have been a significant contributor to its revenue growth. Anteris Technologies Global Corp. offers a range of cloud-based solutions, including data analytics, artificial intelligence, and cybersecurity. These services have been in high demand, driven by the increasing need for businesses to adopt cloud-based technologies to stay competitive.

Data analytics: Anteris Technologies Global Corp. provides advanced data analytics solutions to help businesses make data-driven decisions.

Artificial intelligence: The company offers AI-powered solutions to automate tasks and improve efficiency.

Cybersecurity: Anteris Technologies Global Corp. provides robust cybersecurity solutions to protect businesses from cyber threats. The company’s innovative technologies have also played a significant role in its revenue growth.

Improved patient outcomes and reduced complications.The DurAVR THV System: A Breakthrough in Cardiac Surgery

The DurAVR THV system is a groundbreaking innovation in cardiac surgery, revolutionizing the treatment of aortic valve disease.

The IDE application will be submitted to the FDA in conjunction with the Pivotal Trial.Anteris’ Strategy for FDA Approval

Anteris is taking a strategic approach to FDA approval for its DurAVR THV system. The company is focusing on the Pivotal Trial, which will provide the necessary data to support the approval of the device. The trial will be conducted in conjunction with the IDE application, which will be submitted to the FDA. • The Pivotal Trial will be a randomized, controlled study that will compare the DurAVR THV system to a standard treatment. • The trial will be conducted at multiple sites across the United States. • The trial will enroll approximately 100 patients. • The trial will assess the safety and efficacy of the DurAVR THV system.

Conducting preclinical studies to demonstrate the safety and efficacy of the DurAVR THV system.

Submitting a premarket notification to the FDA to inform them of the device.

Engaging with regulatory experts to ensure compliance with FDA regulations.

Developing a comprehensive regulatory strategy to support the approval of the device.The Importance of IDE Application

The IDE application is a critical component of the FDA approval process. The IDE application will provide the FDA with the necessary information to evaluate the safety and efficacy of the DurAVR THV system.

EU-EFS: A Groundbreaking Procedure for Structural Heart Disease

The EU-EFS, or European Union-Enhanced Flow Sensing, is a revolutionary medical procedure designed to treat structural heart disease.

Industry Recognition and Awards

The Company’s innovative approach to treating aortic stenosis has garnered significant attention from the medical community, resulting in several prestigious awards and recognitions. • The DurAVR THV system has been recognized as a Breakthrough Therapy by the FDA, a designation that acknowledges the system’s potential to revolutionize the treatment of aortic stenosis. • The Company has also received the Best of MedTech award from the Medical Device Manufacturers Association (MDMA), a testament to its commitment to innovation and excellence in medical technology.

The Significance of the DurAVR THV Pivotal Trial

The DurAVR THV Pivotal Trial is a groundbreaking study that aims to evaluate the safety and efficacy of the DurAVR Transcatheter Aortic Valve Replacement (TAVR) system.

Financial Highlights

The financial results of Anteris for the year ended December 31, 2024, are a reflection of the company’s efforts to adapt to the changing market conditions and customer needs. The company’s focus on innovation and quality has led to a significant increase in sales of its tissue products. • Key highlights of the financial results include:

Net Sales of $7 million

Sales of tissue products accounting for the majority of revenue

Significant increase in sales compared to previous years

The company’s decision to cease manufacturing products for LeMaitre in January 2025, marks a strategic shift in its business operations. This move is expected to have a positive impact on the company’s financial performance in the long run.

High-quality materials and manufacturing processes

Customizable products to meet specific customer needs

Wide range of products for various medical applications

The company’s decision to cease manufacturing products for LeMaitre is expected to have a positive impact on its financial performance.

The convertible note facility is convertible into common stock at a price of $2.20 per share. The conversion price is lower than the IPO price of $3.00 per share. This lower price reflects the reduced risk profile of the company, as evidenced by the Bridging Facility.

Anteris is a global structural heart company committed to designing, developing, and commercializing cutting-edge medical devices to restore healthy heart function. Anteris’ lead product, the DurAVR® Transcatheter Heart Valve (“THV”), was designed in partnership with the world’s leading interventional cardiologists and cardiac surgeons.

This announcement contains forward-looking statements. Forward-looking statements are subject to a number of risks, uncertainties, and assumptions, including those described under “Risk Factors” in Anteris’ registration statement filed on 10 December 2024 with the SEC and ASX. Anteris Technologies Inc. is a company that specializes in the development of advanced materials and technologies for the automotive industry.

The company specializes in developing innovative solutions for the global life science industry. Anteris Technologies Global Corp. has developed a range of products and services that cater to the needs of various stakeholders in the life science sector, including researchers, clinicians, and regulatory agencies.

*Regulatory Compliance Solutions*: Anteris Technologies Global Corp. provides regulatory compliance solutions that help life science companies navigate the complex regulatory landscape. These solutions include regulatory consulting, regulatory affairs, and compliance training.

*Research and Development Support*: The company offers research and development support services that help life science companies accelerate their research and development processes. These services include research design, data analysis, and regulatory submission support.

*Clinical Trial Management*: Anteris Technologies Global Corp. provides clinical trial management services that help life science companies manage their clinical trials effectively. These services include clinical trial design, patient recruitment, and data management.